{"id":"d1eff9e96ac6","type":"article","url":"https://hartvaat.nl/2016/06/01/familiaire-belasting-en-statine-initiatie-bij-intermediair-cardiovasculair-risic/","title":"Familiaire belasting en statine-initiatie bij intermediair cardiovasculair risico: HOPE-3-analyse","title_en":"Association of a Family History of Coronary Heart Disease With Initiation of Statin Therapy in Individuals at Intermediate Risk: Post Hoc Analysis of a Randomized Clinical Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts"],"tags":["acuut-hartfalen","ouderen"],"journal":"JAMA cardiology","doi":"10.1001/jamacardio.2016.0227","source_url":"https://doi.org/10.1001/jamacardio.2016.0227","authors":["Maya S Safarova","Kent R Bailey","Iftikhar J Kullo"],"significance":6,"published":"2016-06-01","source_date":"2016-06-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This HOPE-3 analysis examined the role of family history in the decision to initiate statin therapy in intermediate-risk individuals, exploring whether genetic predisposition modifies the benefit of primary prevention.","created":"2026-07-03T10:26:09Z","updated":"2026-07-03T13:25:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"JAMA Cardiology analyse van HOPE-3 naar de rol van familiaire belasting bij de beslissing om statinetherapie te starten bij personen met intermediair risico. Onderzoekt de meerwaarde van familieanamnese voor risicostratificatie.","abstract_original":""}